CD274 and neoplasm: At a median follow-up of 23.7 months, the OS and PFS ranged from 8.2 to 28.5 months and 4.0 to 28.5 months, respectively; the 12-month and 24-month OS rates were 85% and 69.6%; the PFS rates were 80.0% and 65%; and the tumor PD-L1 expression was associated with OS [136].